These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 36354771)

  • 1. Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity.
    Zhang X; Sun Y; Zhang Y; Fang F; Liu J; Xia Y; Liu Y
    J Cardiovasc Dev Dis; 2022 Oct; 9(11):. PubMed ID: 36354771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Biomarkers in Cardio-Oncology.
    Ananthan K; Lyon AR
    J Cardiovasc Transl Res; 2020 Jun; 13(3):431-450. PubMed ID: 32642841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction.
    Xiao H; Wang X; Li S; Liu Y; Cui Y; Deng X
    Front Cardiovasc Med; 2021; 8():753313. PubMed ID: 34859069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
    Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
    J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond.
    Attanasio U; Di Sarro E; Tricarico L; Di Lisi D; Armentaro G; Miceli S; Fioretti F; Deidda M; Correale M; Novo G; Sciacqua A; Nodari S; Cadeddu C; Tocchetti CG; Palazzuoli A; Mercurio V
    Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating biomarkers for management of cancer therapeutics-related cardiac dysfunction.
    Tonry C; Russell-Hallinan A; McCune C; Collier P; Harbinson M; Dixon L; Watson CJ
    Cardiovasc Res; 2023 May; 119(3):710-728. PubMed ID: 35640873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy-Related Cardiac Dysfunction.
    Mecinaj A; Gulati G; Ree AH; Gravdehaug B; Røsjø H; Steine K; Wisløff T; Geisler J; Omland T; Heck SL
    JACC CardioOncol; 2024 Feb; 6(1):83-95. PubMed ID: 38510299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for early detection of cardiotoxicities from anticancer therapy in adults: evolving imaging techniques and emerging serum biomarkers.
    Akhter N; Murtagh G; Yancy C
    Future Oncol; 2015; 11(14):2093-103. PubMed ID: 26198839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodal assessment of acute cardiac toxicity induced by thoracic radiotherapy in cancer patients. Study protocol.
    Merino T; Pinto MP; Orellana MP; Martinez G; Andía M; Munoz-Schuffenegger P; Acevedo F; Gabrielli L; Sanchez C; Pereira J
    BMC Cancer; 2021 Oct; 21(1):1114. PubMed ID: 34663256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Cardiac Biomarkers in Cancer Patients.
    Semeraro GC; Cipolla CM; Cardinale DM
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy?: Impact of Temporal and Observer Variability.
    Altaha MA; Nolan M; Marwick TH; Somerset E; Houbois C; Amir E; Yip P; Connelly KA; Michalowska M; Sussman MS; Wintersperger BJ; Thavendiranathan P
    JACC Cardiovasc Imaging; 2020 Apr; 13(4):951-962. PubMed ID: 31864977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy.
    Henri C; Heinonen T; Tardif JC
    Biomark Cancer; 2016; 8(Suppl 2):39-45. PubMed ID: 27257396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.
    Gulati G; Heck SL; Røsjø H; Ree AH; Hoffmann P; Hagve TA; Norseth J; Gravdehaug B; Steine K; Geisler J; Omland T
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29118031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardio-toxicity among patients with sarcoma: a cardio-oncology registry.
    Shamai S; Rozenbaum Z; Merimsky O; Derakhshesh M; Moshkovits Y; Arnold J; Topilsky Y; Arbel Y; Laufer-Perl M
    BMC Cancer; 2020 Jun; 20(1):609. PubMed ID: 32605637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of reduced global longitudinal strain with cancer therapy-related cardiac dysfunction among patients receiving cancer therapy.
    Laufer-Perl M; Arnold JH; Mor L; Amrami N; Derakhshesh M; Moshkovits Y; Sadeh B; Arbel Y; Topilsky Y; Rozenbaum Z
    Clin Res Cardiol; 2020 Feb; 109(2):255-262. PubMed ID: 31214777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Biomarkers in Detection of Cardio-toxicity.
    Shah KS; Yang EH; Maisel AS; Fonarow GC
    Curr Oncol Rep; 2017 Jun; 19(6):42. PubMed ID: 28421484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial.
    Meessen JMTA; Cardinale D; Ciceri F; Sandri MT; Civelli M; Bottazzi B; Cucchi G; Menatti E; Mangiavacchi M; Condorelli G; Barbieri E; Gori S; Colombo A; Curigliano G; Salvatici M; Pastori P; Ghisoni F; Bianchi A; Falci C; Cortesi P; Farolfi A; Monopoli A; Milandri C; Bregni M; Malossi A; Nassiacos D; Verusio C; Staszewsky L; Leone R; Novelli D; Balconi G; Nicolis EB; Franzosi MG; Masson S; Garlanda C; Mantovani A; Cipolla CM; Latini R;
    ESC Heart Fail; 2020 Aug; 7(4):1452-1466. PubMed ID: 32358917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Machine Learning-Based Risk Assessment for Cancer Therapy-Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients.
    Zhou Y; Hou Y; Hussain M; Brown SA; Budd T; Tang WHW; Abraham J; Xu B; Shah C; Moudgil R; Popovic Z; Cho L; Kanj M; Watson C; Griffin B; Chung MK; Kapadia S; Svensson L; Collier P; Cheng F
    J Am Heart Assoc; 2020 Dec; 9(23):e019628. PubMed ID: 33241727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.
    Bergler-Klein J; Rainer PP; Wallner M; Zaruba MM; Dörler J; Böhmer A; Buchacher T; Frey M; Adlbrecht C; Bartsch R; Gyöngyösi M; Fürst UM
    Wien Klin Wochenschr; 2022 Sep; 134(17-18):654-674. PubMed ID: 35507087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
    Pudil R; Mueller C; Čelutkienė J; Henriksen PA; Lenihan D; Dent S; Barac A; Stanway S; Moslehi J; Suter TM; Ky B; Štěrba M; Cardinale D; Cohen-Solal A; Tocchetti CG; Farmakis D; Bergler-Klein J; Anker MS; Von Haehling S; Belenkov Y; Iakobishvili Z; Maack C; Ciardiello F; Ruschitzka F; Coats AJS; Seferovic P; Lainscak M; Piepoli MF; Chioncel O; Bax J; Hulot JS; Skouri H; Hägler-Laube ES; Asteggiano R; Fernandez TL; de Boer RA; Lyon AR
    Eur J Heart Fail; 2020 Nov; 22(11):1966-1983. PubMed ID: 33006257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.